Finance

Lists
ABT:NYSE
Abbott Laboratories
103,87 US$
-0,58%
(-0,61) 1D
103,87 US$
0,00% (0,00)
After hours
Closed: 19 ნოე, 16:03:13 GMT-5  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for ABT...
Open
104,93 US$
High
105,84 US$
Low
103,61 US$
Mkt. cap
179,90 მლრ.
Avg. vol.
9,25 მლნ.
Volume
7,51 მლნ.
Dividend
2,43%
Quarterly dividend
0,63 US$
Ex-dividend date
15 ოქტ. 2026
P/E ratio
38,52
52-wk high
129,85 US$
52-wk low
81,97 US$
EPS
2,70 US$
Beta
0,54
Shares outstanding
1,73 მლრდ.
No. of employees
115 ათ.
Open
104,93 US$
High
105,84 US$
Low
103,61 US$
Mkt. cap
179,90 მლრ.
Avg. vol.
9,25 მლნ.
Volume
7,51 მლნ.
Dividend
2,43%
Quarterly dividend
0,63 US$
Ex-dividend date
15 ოქტ. 2026
P/E ratio
38,52
52-wk high
129,85 US$
52-wk low
81,97 US$
EPS
2,70 US$
Beta
0,54
Shares outstanding
1,73 მლრდ.
No. of employees
115 ათ.
News stories
From web sources and news partners
Investing.com
Investing.com
·
8 საათის წინ
Abbott initiates trial for Encantor heart valve system
Profile
Abbott Laboratories, commonly known as Abbott, is an American multinational medical devices and health care company founded in Chicago with headquarters in Abbott Park, Illinois. The company produces pharmaceuticals for sale outside the United States, diagnostic products, nutritional products, and medical devices. Abbott operates in over 160 countries and sources from at least 62 suppliers worldwide. Abbott's products include Pedialyte, Similac, BinaxNOW, Ensure, Glucerna, ZonePerfect, FreeStyle Libre, i-STAT and MitraClip. The company is ranked 107th on the Fortune 500 and 144th on the Forbes Global 2000. Wikipedia
About Abbott Laboratories
CEOრობერ ბი ფორდ
Employees115 ათ.
Founded1888
Headquartersჩიკაგო, ილინოისი, ამერიკის შეერთებული შტატები
SectorHealth Care
IndustryMedical device
Websiteabbott.com
Analyst ratings
Based on 18 analysts giving stock ratings to ABT in the past 3 months
Strong buy
Buy
17
Hold
1
Sell
0
12-month forecast
Based on 18 Wall Street analysts offering 12 month price targets for ABT in the last 3 months.
Highest
Current 103,87 US$
135,00 US$ (+29,97%)
Average
122,19 US$ (+17,64%)
Lowest
115,00 US$ (+10,72%)
Analyst
Recommendation
Action
Price target
Projected
Date
Mike Kratky
Leerink Partners
Buy
Upgraded
124,00 US$
+19,4%
11/19/2026
Travis Steed
Bank of America Securities
Buy
Maintained
125,00 US$
+20,3%
11/09/2026
Adam Maeder
Piper Sandler
Buy
Maintained
118,00 US$
+13,6%
11/02/2026
David Toung
Argus Research
Hold
Downgraded
-
-
10/26/2026
Vijay Kumar
Evercore ISI
Buy
Maintained
120,00 US$
+15,5%
10/23/2026
Rick Wise
Stifel Nicolaus
Buy
Maintained
120,00 US$
+15,5%
10/22/2026
Unknown Analyst
Oppenheimer
Buy
Maintained
115,00 US$
+10,7%
10/22/2026
Josh Jennings
TD Cowen
Buy
Reiterated
118,00 US$
+13,6%
10/22/2026
Kendall Au
RBC Capital
Buy
Maintained
125,00 US$
+20,3%
10/21/2026
Shagun Singh Chadha
RBC Capital
Buy
Reiterated
125,00 US$
+20,3%
10/21/2026
Robbie Marcus
J.P. Morgan
Buy
Maintained
118,00 US$
+13,6%
10/22/2026
David Rescott
Robert W. Baird
Buy
Maintained
123,00 US$
+18,4%
10/22/2026
Marie Thibault
BTIG
Buy
Maintained
125,00 US$
+20,3%
10/21/2026
Larry Biegelsen
Wells Fargo
Buy
Maintained
120,00 US$
+15,5%
10/23/2026
Christopher Pasquale
Barclays
Buy
Maintained
120,00 US$
+15,5%
10/22/2026
Joanne Wuensch
Citi
Buy
Reiterated
122,00 US$
+17,5%
10/22/2026
Unknown Analyst
Leerink Partners
Hold
Maintained
-
-
10/12/2026
Matt Miksic
Barclays
Buy
Maintained
120,00 US$
+15,5%
10/07/2026
Himanshu Patel
J.P. Morgan
Buy
Initiated
120,00 US$
+15,5%
10/07/2026
Ed Ridley-Day
Rothschild & Co Redburn
Buy
Upgraded
127,00 US$
+22,3%
10/02/2026
Matthew Taylor
Jefferies
Buy
Reiterated
135,00 US$
+30%
08/21/2026
Brandon Vazquez
William Blair
Buy
Maintained
-
-
08/21/2026
Michael Polark
Wolfe Research
Buy
Upgraded
130,00 US$
+25,2%
08/13/2026
Danielle Antalffy
UBS
Buy
Reiterated
125,00 US$
+20,3%
07/28/2026
Patrick Wood
UBS
Buy
Reiterated
125,00 US$
+20,3%
07/28/2026
Unknown Analyst
Jefferies
Buy
Reiterated
135,00 US$
+30%
07/17/2026
Jayson Bedford
Raymond James
Buy
Maintained
-
-
07/17/2026
Unknown Analyst
J.P. Morgan
Buy
Maintained
110,00 US$
+5,9%
06/29/2026
David Roman
Goldman Sachs
Buy
Maintained
113,00 US$
+8,8%
05/31/2026
Narumi Nakagiri
Daiwa
Hold
Downgraded
92,00 US$
-11,4%
04/21/2026
Anthony Petrone
Mizuho Securities
Hold
Maintained
115,00 US$
+10,7%
04/20/2026
Suraj Kalia
Oppenheimer
Buy
Maintained
115,00 US$
+10,7%
04/17/2026
Bruce Jackson
Benchmark Co.
Buy
Maintained
120,00 US$
+15,5%
04/17/2026
Unknown Analyst
Goldman Sachs
Buy
Reiterated
121,00 US$
+16,5%
04/09/2026
Unknown Analyst
Erste Group
Hold
Maintained
-
-
04/01/2026
Last report
21 ოქტ. 2026
Fiscal period
Q3 2026
1,42 US$ / 1,42 US$
+0,03%beat
Revenue / Est. (USD)
13,01 მლრდ. / 12,99 მლრდ.
+0,18%beat
Fiscal Q3 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
დეკ. 2025
მარ. 2026
ივნ. 2026
სექ. 2026
Revenue
11,46 მლრდ.
11,16 მლრდ.
12,59 მლრდ.
13,01 მლრდ.
Cost of goods sold
4,91 მლრდ.
4,89 მლრდ.
5,32 მლრდ.
5,63 მლრდ.
Cost of revenue
4,91 მლრდ.
4,89 მლრდ.
5,32 მლრდ.
5,63 მლრდ.
Research and development expenses
720,00 მლნ.
767,00 მლნ.
892,00 მლნ.
920,00 მლნ.
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
2,93 მლრდ.
3,58 მლრდ.
3,87 მლრდ.
4,11 მლრდ.
Operating expense
4,07 მლრდ.
4,77 მლრდ.
5,42 მლრდ.
5,87 მლრდ.
Total operating expenses
8,98 მლრდ.
9,66 მლრდ.
10,74 მლრდ.
11,50 მლრდ.
Operating income
2,48 მლრდ.
1,50 მლრდ.
1,85 მლრდ.
1,52 მლრდ.
Other non operating income
-15,00 მლნ.
-
-25,00 მლნ.
5,00 მლნ.
EBT including unusual items
2,36 მლრდ.
1,45 მლრდ.
1,52 მლრდ.
1,23 მლრდ.
EBT excluding unusual items
2,44 მლრდ.
1,45 მლრდ.
1,52 მლრდ.
1,23 მლრდ.
Income tax expense
582,00 მლნ.
372,00 მლნ.
596,00 მლნ.
311,00 მლნ.
Effective tax rate
24,68%
25,67%
39,11%
25,26%
Other operating expenses
-
-
-
-
Net income
1,78 მლრდ.
1,08 მლრდ.
928,00 მლნ.
920,00 მლნ.
Net profit margin
15,50%
9,65%
7,37%
7,07%
Earnings per share
1,50
1,15
1,31
1,42
Interest and investment income
78,00 მლნ.
106,00 მლნ.
52,00 მლნ.
53,00 მლნ.
Interest expense
-120,00 მლნ.
-174,00 მლნ.
-351,00 მლნ.
-350,00 მლნ.
Net interest expenses
-42,00 მლნ.
-68,00 მლნ.
-299,00 მლნ.
-297,00 მლნ.
Depreciation and amortization charges
-
-
-
-
EBITDA
3,27 მლრდ.
2,31 მლრდ.
2,91 მლრდ.
2,77 მლრდ.
Gain or loss from assets sale
65,00 მლნ.
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
Upcoming events
AI content may include mistakes. Learn more
Google აპები